Wistar scientists develop new bispecific T cell engager to target ovarian cancer
Wistar scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian cancer in preclinical studies.
Wistar scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian cancer in preclinical studies.